B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.73%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.16B
AUM Growth
+$104M
Cap. Flow
-$1.09B
Cap. Flow %
-34.59%
Top 10 Hldgs %
35.35%
Holding
97
New
14
Increased
28
Reduced
11
Closed
11
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
BCYC icon
Bicycle Therapeutics
BCYC
+$29.5M
2
ETNB icon
89bio
ETNB
+$26.7M
3
IMCR icon
Immunocore
IMCR
+$26M
4
TMO icon
Thermo Fisher Scientific
TMO
+$25.8M
5
INSP icon
Inspire Medical Systems
INSP
+$25.3M

Top Sells

Rank Stock Value
1
DICE icon
DICE Therapeutics, Inc. Common Stock
DICE
+$47.8M
2
BIIB icon
Biogen
BIIB
+$34.7M
3
ALGN icon
Align Technology
ALGN
+$34.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$30.1M
5
GKOS icon
Glaukos
GKOS
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 51.8%
2 Miscellaneous 47.89%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ETNB icon
26
DELISTED
89bio
ETNB
$24.6M 0.78%
+1,590,387
New +$26.7M
2023 Q3
0 quarters
PEN icon
27
Penumbra
PEN
$12.6B
$23.1M 0.73%
95,315
+29,471
+45% +$8.18M
2022 Q4
3 quarters
GH icon
28
Guardant Health
GH
$21.9B
$20.4M 0.65%
689,000
+419,000
+155% +$14.7M
2023 Q2
1 quarter
LNTH icon
29
Lantheus
LNTH
$6.53B
$20M 0.63%
+288,300
New +$21.1M
2023 Q3
0 quarters
INSP icon
30
Inspire Medical Systems
INSP
$1.97B
$19.9M 0.63%
+100,300
New +$25.3M
2023 Q3
0 quarters
AXNX icon
31
DELISTED
Axonics, Inc. Common Stock
AXNX
$19.9M 0.63%
354,527
-219,264
-38% -$12.3M
2023 Q1
2 quarters
HLVX icon
32
DELISTED
HilleVax
HLVX
$19.5M 0.62%
1,449,246
+200,000
+16% +$2.81M
2022 Q4
3 quarters
MLYS icon
33
Mineralys Therapeutics
MLYS
$1.84B
$19.2M 0.61%
2,023,900
+1,473,600
+268% +$19.2M
2023 Q1
2 quarters
DHR icon
34
Danaher
DHR
$158B
$19.2M 0.61%
87,082
+24,591
+39% +$5.48M
2023 Q2
1 quarter
ANAB icon
35
AnaptysBio
ANAB
$1.4B
$18.9M 0.6%
1,049,823
-104,600
-9% -$2M
2022 Q4
3 quarters
RGEN icon
36
Repligen
RGEN
$11.3B
$18.8M 0.6%
118,400
+26,400
+29% +$4.32M
2023 Q2
1 quarter
PTGX icon
37
Protagonist Therapeutics
PTGX
$8.82B
$18.5M 0.58%
+1,109,150
New +$21.5M
2023 Q3
0 quarters
RAPT icon
38
DELISTED
RAPT Therapeutics
RAPT
$18M 0.57%
135,314
+12,264
+10% +$2M
2023 Q2
1 quarter
CGEM icon
39
Cullinan Oncology
CGEM
$878M
$17.3M 0.55%
1,908,865
– –
2023 Q2
1 quarter
INCY icon
40
Incyte
INCY
$22.6B
$17M 0.54%
+294,900
New +$18.6M
2023 Q3
0 quarters
TMDX icon
41
Transmedics
TMDX
$2.62B
$16.8M 0.53%
+307,200
New +$22.1M
2023 Q3
0 quarters
DBVT icon
42
DBV Technologies S.A. American Depositary Shares
DBVT
$557M
$16.5M 0.52%
1,210,779
– –
2022 Q4
3 quarters
DYN icon
43
Dyne Therapeutics
DYN
$2.81B
$16.3M 0.52%
1,821,972
+444,100
+32% +$4.78M
2022 Q4
3 quarters
TERN icon
44
DELISTED
Terns Pharmaceuticals
TERN
$14.3M 0.45%
2,840,052
+997,700
+54% +$6.33M
2023 Q1
2 quarters
IRWD icon
45
Ironwood Pharmaceuticals
IRWD
$595M
$13M 0.41%
+1,348,099
New +$13.2M
2023 Q3
0 quarters
CMPX icon
46
Compass Therapeutics
CMPX
$158M
$11.7M 0.37%
5,954,273
– –
2022 Q4
3 quarters
ENTA icon
47
Enanta Pharmaceuticals
ENTA
$326M
$11.6M 0.37%
1,038,310
– –
2022 Q4
3 quarters
PRCT icon
48
Procept Biorobotics
PRCT
$1B
$10.9M 0.34%
+331,061
New +$11.3M
2023 Q3
0 quarters
THRD icon
49
DELISTED
Third Harmonic Bio
THRD
$10.6M 0.33%
+1,653,991
New +$10.1M
2023 Q3
0 quarters
APGE icon
50
DELISTED
Apogee Therapeutics
APGE
$10.5M 0.33%
+491,113
New +$10.8M
2023 Q3
0 quarters
1
2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q3 2023 Portfolio in Review

As of Q3 2023, Braidwell held 97 positions worth $3.16B, up 3.4% from $3.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $1.09B in Q3 2023, closing 11 positions and reducing 11 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Bicycle Therapeutics worth $25.9M.

  • Braidwell's largest Q3 2023 buy was Bicycle Therapeutics: 1,289,872 shares worth $25.9M.
  • Braidwell added most to Immunocore in Q3 2023, an estimated $26M increase.
  • Braidwell's biggest Q3 2023 reduction was Align Technology, cutting an estimated $34.1M.
  • Braidwell fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • Braidwell's ten largest holdings make up 35% of its $3.16B portfolio in Q3 2023.
  • Braidwell opened 14 new positions and closed 11 in Q3 2023.
  • Braidwell's portfolio value rose 3.4% quarter-over-quarter to $3.16B.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.